Update shared on16 Sep 2025
Fair value Increased 0.48%Agilent Technologies’ fair value estimates have remained stable, as reflected by marginal changes in both the consensus analyst price target (up slightly to $138.83) and the forward P/E (now 27.33x).
What's in the News
- Raised full-year 2025 revenue guidance to $6.91–$6.93 billion, up 6.2–6.5% reported and 4.3–4.6% core, reflecting a $150 million increase at the midpoint and 1.5 points higher core growth.
- Issued fourth-quarter revenue guidance of $1.822–$1.842 billion, representing 7.1–8.3% reported and 4.8–6.0% core growth.
- FDA approved Agilent’s MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic for colorectal cancer, developed with Bristol Myers Squibb for Opdivo and Yervoy therapies.
- Established an Agilent Center of Excellence with Georgia Tech to advance research in environmental health, water recycling, and sustainability, leveraging Agilent’s analytical technologies.
- Chief Financial Officer Bob McMahon to step down, with Rodney Gonsalves appointed as interim CFO pending a successor.
Valuation Changes
Summary of Valuation Changes for Agilent Technologies
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $138.17 to $138.83.
- The Future P/E for Agilent Technologies remained effectively unchanged, moving only marginally from 27.20x to 27.33x.
- The Discount Rate for Agilent Technologies remained effectively unchanged, at 7.39%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.